A detailed history of Signaturefd, LLC transactions in Blueprint Medicines Corp stock. As of the latest transaction made, Signaturefd, LLC holds 169 shares of BPMC stock, worth $15,864. This represents 0.0% of its overall portfolio holdings.

Number of Shares
169
Previous 187 9.63%
Holding current value
$15,864
Previous $20,000 25.0%
% of portfolio
0.0%
Previous 0.0%

Shares

16 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 21, 2024

SELL
$84.1 - $120.5 $1,513 - $2,169
-18 Reduced 9.63%
169 $15,000
Q2 2024

Jul 29, 2024

BUY
$85.18 - $108.78 $3,236 - $4,133
38 Added 25.5%
187 $20,000
Q4 2023

Jan 31, 2024

SELL
$43.96 - $92.84 $5,978 - $12,626
-136 Reduced 47.72%
149 $13,000
Q3 2023

Nov 03, 2023

SELL
$46.9 - $66.0 $328 - $462
-7 Reduced 2.4%
285 $14,000
Q2 2023

Aug 01, 2023

BUY
$42.2 - $66.37 $5,190 - $8,163
123 Added 72.78%
292 $18,000
Q1 2023

Apr 28, 2023

BUY
$37.97 - $50.0 $1,974 - $2,600
52 Added 44.44%
169 $7,000
Q4 2022

Jan 27, 2023

SELL
$41.06 - $66.48 $3,490 - $5,650
-85 Reduced 42.08%
117 $5,000
Q3 2022

Nov 08, 2022

SELL
$49.93 - $77.7 $3,045 - $4,739
-61 Reduced 23.19%
202 $13,000
Q2 2022

Aug 10, 2022

BUY
$45.23 - $70.15 $5,608 - $8,698
124 Added 89.21%
263 $13,000
Q1 2022

May 02, 2022

BUY
$54.1 - $110.08 $1,731 - $3,522
32 Added 29.91%
139 $9,000
Q4 2021

Jan 25, 2022

BUY
$94.25 - $115.99 $1,602 - $1,971
17 Added 18.89%
107 $11,000
Q3 2021

Oct 28, 2021

BUY
$80.98 - $109.47 $161 - $218
2 Added 2.27%
90 $9,000
Q2 2021

Jul 26, 2021

BUY
$82.78 - $101.0 $82 - $101
1 Added 1.15%
88 $8,000
Q1 2021

Apr 30, 2021

BUY
$90.71 - $108.28 $90 - $108
1 Added 1.16%
87 $8,000
Q3 2020

Nov 03, 2020

BUY
$66.45 - $92.7 $1,329 - $1,854
20 Added 30.3%
86 $8,000
Q1 2020

Apr 23, 2020

BUY
$48.11 - $82.22 $3,175 - $5,426
66 New
66 $4,000

Others Institutions Holding BPMC

About Blueprint Medicines Corp


  • Ticker BPMC
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 59,719,600
  • Market Cap $5.61B
  • Description
  • Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibit...
More about BPMC
Track This Portfolio

Track Signaturefd, LLC Portfolio

Follow Signaturefd, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Signaturefd, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Signaturefd, LLC with notifications on news.